Synthesis, isomerisation and biological properties of mononuclear ruthenium complexes containing the bis[4(4'-methyl-2,2'-bipyridyl)]-1,7-heptane ligand

Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review

The widespread use of antibiotics has resulted in the emergence of drug-resistant populations of microorganisms. Clearly, one can see the need to develop new, more effective, antimicrobial agents that go beyond the explored 'chemical space'. In this regard, their unique modes of action (e.g., reactive oxygen species (ROS) generation, redox activation, ligand exchange, depletion of substrates involved in vital cellular processes) render metal complexes as promising drug candidates. Several Ru (II/III) complexes have been included in, or are currently undergoing, clinical trials as anticancer agents. Based on the in-depth knowledge of their chemical properties and biological behavior, the interest in developing new ruthenium compounds as antibiotic, antifungal, antiparasitic, or antiviral drugs has risen. This review will discuss the advantages and disadvantages of Ru (II/III) frameworks as antimicrobial agents. Some aspects regarding the relationship between their chemical structure and mechanism of action, cellular localization, and/or metabolism of the ruthenium complexes in bacterial and eukaryotic cells are discussed as well. Regarding the antiviral activity, in light of current events related to the Covid-19 pandemic, the Ru (II/III) compounds used against SARS-CoV-2 (e.g., BOLD-100) are also reviewed herein.

Polymeric ruthenium precursor as a photoactivated antimicrobial agent

Ruthenium coordination compounds have demonstrated a promising anticancer and antibacterial activity, but their poor water solubility and low stability under physiological conditions may limit their therapeutic applications. Physical encapsulation or covalent conjugation with polymers may overcome these drawbacks, but generally involve multistep reactions and purification processes. In this work, the antibacterial activity of the polymeric precursor dicarbonyldichlororuthenium (II) [Ru(CO)₂Cl₂]_n has been studied against Escherichia coli and Staphylococcus aureus. This Ru-carbonyl precursor shows minimum inhibitory concentration at nanogram per millilitre, which renders it a novel antimicrobial polymer without any organic ligands. Besides, [Ru(CO)₂Cl₂]_n antimicrobial activity is markedly boosted under photoirradiation, which can be ascribed to the enhanced generation of reactive oxygen species under UV irradiation. [Ru(CO)₂Cl₂]_n has been able to inhibit bacterial growth via the disruption of bacterial membranes and triggering upregulation of stress responses as shown in microscopic measurements. The activity of polymeric ruthenium as an antibacterial material is significant even at 6.6 ng/mL while remaining biocompatible to the mammalian cells at much higher concentrations. This study proves that this simple precursor, [Ru(CO)₂Cl₂]_n, can be used as an antimicrobial compound with high activity and a low toxicity profile in the context of need for new antimicrobial agents to fight bacterial infections.

Interaction of the Large Host Q[10] with Metal Polypyridyl Complexes: Binding Modes and Effects on Luminescence

Aqueous solution state host-guest systems have been studied, comprising the large host cucurbit[10]uril with luminescent cationic tris(polypyridyl) (PP) metal complexes [Ru(PP)₃]²⁺ and [Ir(PP)₃]³⁺. All complexes bind strongly with the host, with the overall complex charge and size having a minor effect on affinity but influencing the association dynamics and contribution from higher-order (1:2) host-guest species. The 1:2 species contributes more significantly to the binding equilibrium in the case of [Ru(phen)₃]²⁺. The effect of the host upon emission is highly variable and depends on the electronic structure of the guest. The metal-to-ligand charge transfer (MLCT) emission of [Ru(PP)₃]²⁺ is strongly quenched, in contrast to the large enhancements seen previously for MLCT emission of iridium cyclometalated complexes, while the ligand-centered emission of [Ir(PP)₃]³⁺ is little affected. The mechanisms of quenching and enhancement are discussed, together with the implications for the design of larger supramolecular assemblies based on these archetypal emitters.

Synthesis and Characterisation of Helicate and Mesocate Forms of a Double-Stranded Diruthenium(II) Complex of a Di(terpyridine) Ligand

A diruthenium(ii) complex involving the di(terpyridine) ligand 1,2-bis{5-(5″-methyl-2,2′:6′,2″-terpyridinyl)}ethane was synthesised by heating an equimolar ratio of RuCl3 and the ligand under reflux conditions in ethylene glycol for 3 days, realising double-stranded helicate and mesocate forms which were chromatographically separated. The two species were obtained in relatively low yield (each ~7–9%) from the reaction mixture. X-Ray structural studies revealed differences in the cavity sizes of the two structures, with the helicate structure having a significantly smaller cavity. Furthermore, the helicate and mesocate forms pack with notably different arrangements of the structures with the helicate having large solvent and anion filled pores. 1D/2D NMR studies revealed rigidity in the mesocate structure relative to that of the helicate, such that the –CH2CH2– signal was split in the former and appeared as a singlet in the latter. In a manner analogous to the behaviour of the parent [Ru(tpy)2]2+ coordination moiety (tpy=2,2′:6′,2″-terpyridine), photophysical studies indicated that both the helicate and mesocate forms were non-emissive at ~610nm at room temperature, but at 77K in n-butyronitrile, both isomers showed emission at ~610nm (λex 472nm). However, the temporal emission characteristics were very different: time-resolved studies showed the emission of the helicate species decayed with a dominant emission lifetime of ~10 μs (similar to the emissive properties of free [Ru(tpy)2]2+ under the same conditions), whereas for the mesocate the emission lifetime was at least three orders of magnitude lower (~4 ns).

Eukaryotic Cell Toxicity and HSA Binding of [Ru(Me4phen)(bb7)]2+ and the Effect of Encapsulation in Cucurbit[10]uril

The toxicity (IC₅₀) of a series of mononuclear ruthenium complexes containing bis[4(4′-methyl-2,2′-bipyridyl)]-1,n-alkane (bb_n) as a tetradentate ligand against three eukaryotic cell lines—BHK (baby hamster kidney), Caco-2 (heterogeneous human epithelial colorectal adenocarcinoma) and Hep-G2 (liver carcinoma)—have been determined. The results demonstrate that cis-α-[Ru(Me₄phen)(bb₇)]²⁺ (designated as α-Me₄phen-bb₇, where Me₄phen = 3,4,7,8-tetramethyl-1,10-phenanthroline) showed little toxicity toward the three cell lines, and was considerably less toxic than cis-α-[Ru(phen)(bb₁₂)]²⁺ (α-phen-bb₁₂) and the dinuclear complex [{Ru(phen)₂}₂{μ-bb₁₂}]⁴⁺. Fluorescence spectroscopy was used to study the binding of the ruthenium complexes with human serum albumin (HSA). The binding of α-Me₄phen-bb₇ to the macrocyclic host molecule cucurbit[10]uril (Q[10]) was examined by NMR spectroscopy. Large upfield ¹H NMR chemical shift changes observed for the methylene protons in the bb₇ ligand upon addition of Q[10], coupled with the observation of several intermolecular ROEs in ROESY spectra, indicated that α-Me₄phen-bb₇ bound Q[10] with the bb₇ methylene carbons within the cavity and the metal center positioned outside one of the portals. Simple molecular modeling confirmed the feasibility of the binding model. An α-Me₄phen-bb₇-Q[10] binding constant of 9.9 ± 0.2 × 10⁶ M⁻¹ was determined by luminescence spectroscopy. Q[10]-encapsulation decreased the toxicity of α-Me₄phen-bb₇ against the three eukaryotic cell lines and increased the binding affinity of the ruthenium complex for HSA. Confocal microscopy experiments indicated that the level of accumulation of α-Me₄phen-7 in BHK cells is not significantly affected by Q[10]-encapsulation. Taken together, the combined results suggest that α-Me₄phen-7 could be a good candidate as a new antimicrobial agent, and Q[10]-encapsulation could be a method to improve the pharmacokinetics of the ruthenium complex.